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Introduction: Post-operative radiotherapy (PORT) for stage IIIA completely-resected non-small cell lung cancer
(CR-NSCLC) has been shown to improve local control; however, it is unclear that this translates into a survival
benefit. One explanation is that the detrimental effect of PORT on critical organs at risk (OARs) negates its benefit.
This study reports an in-silico comparative analysis of passive scattering proton therapy (PSPT)- and intensity
modulated proton therapy (IMPT) with intensity modulated photon beam radiotherapy (IMRT) PORT.
Methods: The computed tomography treatment planning scans of ten patients with pathologic stage IIIA
CR-NSCLC treated with IMRT were used. IMRT, PSPT, and IMPT plans were generated and analyzed for dosimetric
endpoints. The proton plans were constructed with two or three beams. All plans were optimized to deliver
50.4 Gy(RBE) in 1.8 Gy(RBE) fractions to the target volume.
Results: IMPT leads to statistically significant reductions in maximum spinal cord, mean lung dose, lung volumes
treated to 5, 10, 20, and 30 Gy (V5, V10, V20, V30), mean heart dose, and heart volume treated to 40 Gy (V40), when
compared with IMRT or PSPT. PSPT reduced lung V5 but increased lung V20, V30, and heart and esophagus V40.
Conclusions: IMPT demonstrates a large decrease in dose to all OARs. PSPT, while reducing the low-dose lung
bath, increases the volume of lung receiving high dose. Reductions are seen in dosimetric parameters predictive
of radiation pneumonitis and cardiac morbidity and mortality. This reduction may correlate with a decrease in
dose-limiting toxicity and improve the therapeutic ratio.
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Outcomes following complete resection of stage IIIA
non-small cell lung cancer (NSCLC) remain poor even
with multimodality therapy. Post-operative radiotherapy
(PORT) for stage IIIA completely-resected (CR) NSCLC
has been previously shown to improve local control [1];
however, it is unclear that this improvement translates
into a survival benefit. The PORT meta-analysis did not
demonstrate an effect on survival in stage III patients* Correspondence: rengan@uw.edu
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reproduction in any medium, provided the or[2]; a proposed explanation is that the detrimental effect
is due to the use of large volumes, high doses, and older
radiation techniques leading to injury to organs-at-risk
(OARs), negating the clinical benefit [3]. Other studies
have shown a survival benefit in CR-NSCLC patients
with ipsilateral mediastinal and/or subcarinal nodal dis-
ease (defined as N2 or Stage IIIA disease) [4,5]. Standard
indications for PORT in the modern era include multiple
positive N2 nodes, high-risk pathologic features, or inad-
equate mediastinal surgical evaluation [6].
This study investigates the dosimetric benefit of pro-
ton therapy in decreasing the toxicity of PORT and
therefore improving the therapeutic ratio. Intensity mod-
ulated radiotherapy (IMRT) has been shown to reduce
dose to OARs and risk of pneumonitis [7]. Proton beaml Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the promise of further reducing toxicity. The radiation
volume for PORT, the mediastinum, is an ideal target for
PBT as it is located midline in the chest with many
lymph node stations lying anteriorly; PBT has the poten-
tial to reduce radiation dose to the lungs, heart, esopha-
gus, and spinal cord.
Several techniques exist for the administration of PBT,
including passive scatter proton therapy (PSPT) and in-
tensity modulated proton therapy (IMPT). While PSPT
decreases dose distally, it is difficult to conform to a
complex target such as the post-operative mediastinal
volume, directly adjacent to critical structures such as
esophagus, spinal cord, and heart. In contrast, IMPT
uses scanning beam technology that modulates inten-
sities of each pencil beam to take into account OAR
constraints and target coverage [8].
This is the first report of the comparative dosimetric
analysis of PSPT- and IMPT-PORT with IMRT- PORT
for CR-NSCLC. Our objective was to assess whether
these techniques reduce the dose to OARs when com-
pared to IMRT, and to determine which treatment plan-
ning approach was superior.Materials and methods
Study population
Ethical approval for this retrospective dosimetric study
was obtained from the institutional review board at the
University of Pennsylvania (number 808624) in compli-
ance with the Helsinki Declaration. Ten patients with
CR-NSCLC and treated with PORT at our institution
from 2006 to 2008 were identified. Indications for PORT
included positive margins and/or positive mediastinal
and/or subcarinal lymph nodes. Five patients had right-
sided tumors and five had left-sided. All patients were
treated with 3D conformal radiotherapy (n = 5 patients)
or IMRT (n = 5 patients).Definition of target volume
Patients underwent three-dimensional CT simulation in
the supine position in a custom mold alpha cradle from
the mandible to the iliac crest (3 mm slices). The clinical
target volume (CTV) was defined as all mediastinal
nodes, the ipsilateral hilum and the bronchial stump.
Level 5 (aortopulmonary window) and level 6 (para-aor-
tic) were only included for left sided tumors. Subcarinal
(station 7) and paratracheal (station 4) lymph node sta-
tions were always included. Borders of lymph node sta-
tions were defined according to the CT-based guidelines
published by Chapet et al. [9]. The planning target vol-
ume (PTV) was defined as the CTV plus a 5 mm mar-
gin. The target volumes were identical in proton and
IMRT plans.Critical structure definition
The following critical normal structures were delineated
on each planning CT scan: body, spinal cord (defined
from 1 cm above the PTV to 1 cm below), heart (defined
from apex to aortic valve), esophagus (defined from hypo-
pharyngeal origin to gastroesophageal junction), contrala-
teral lung, ipsilateral lung, and total lung minus the PTV.
Dose prescription
IMRT and proton plans were optimized to deliver
50.4 Gy (RBE) in 1.8 Gy fractions (28 fractions total).
For PBT, we utilized a generic relative biologic effective-
ness (RBE) of 1.1 as the conversion factor to produce
the effective dose for PBT from the physical dose in Gray,
per the International Commission on Radiation Units
(ICRU) Report 78. All doses are listed in Gy (RBE).
Treatment planning
The IMRT, PSPT, and IMPT plans were generated using
the Eclipse Treatment Planning System, Version 8.9
(Varian Medical Systems, Palo Alto, CA). All plans were
designed by a single physicist experienced in lung and
PBT to minimize variability. The IMRT plans used four
(n = 1 patient) or five (n = 9 patients) co-planar 6-MV
photon fields with a dynamic multileaf collimator (dMLC).
The IMRT normal tissue constraints included the spinal
cord and lung minus the PTV for each patient. Our
planning goals were to provide adequate PTV cove-
rage. The volume of the PTV receiving 95% of the
dose was maintained to be at least 95%, while mini-
mizing the dose delivered to the OARs. Plans were eval-
uated both by analyzing dose-volume histograms (DVHs)
and qualitatively by visually inspecting dose distribution
on axial CT.
For proton planning, in accordance with the report in
ICRU 78, the PTV was defined relative to the CTV on
the basis of lateral uncertainties alone in the range of 0.5
to 1.0 cm. Adjustments were made during the beam-
design process to take into account differences, if any,
between the margins needed to account for uncertainties
along the beam direction (range uncertainties) and those
included in the lateral uncertainty defined PTV [10].
The distal margins used in PSPT were calculated using
3.5% of the distal CTV depth plus 3 mm [10]. The mar-
gin was decreased in IMPT using 3.5% of the distal CTV
depth plus 1 mm as there is no compensator.
For both PSPT and IMPT plans, either a two- or
three-field proton plan (co-planar) was devised in the
following combinations to treat the PTV: left anterior ob-
lique (LAO)/right anterior oblique (RAO), LAO/anterior
posterior (AP), RAO/AP, or RAO/LAO/AP.
For PSPT plans, MLCs were designed to shape each
field laterally, and a compensator was used to shape the
distal portion of the beam to the PTV. To account for
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to ensure sufficient target coverage and proton scattering,
the compensator smearing with a margin of approximately
1 cm was applied in accordance with the method de-
scribed by Moyers et al. A 1 cm border-smoothing margin
was applied to the compensator in order avoid pro-
tons traversing along the compensator wall outside
the CTV which is not shielded by the aperture (MLC
in our case) [10].
For IMPT plans, two to three fields were utilized to
achieve optimum dose coverage to the PTV and dose
sparing to the OARs. Optimization was performed by
the planner adjusting the dose, volume, and penalty of
each objective including targets and OARs. The range of
energies needed for each field was calculated using the
proximal and distal margins of the target structure. All
available preconfigured energy layers within this range
were used in the optimization.
The pencil beam data used in the optimization were
not measured beam data (unavailable at time of study),
but instead calculated data using Geant4-based Monte
Carlo simulation that was customized to match vendor
(IBA Particle Therapy, Belgium) specifications. Monte
Carlo was utilized as it provides a more realistic beam
data specific to our proton system compared to a generic
beam dataset derived from other facilities.
The spot positions within each energy layer are fixed
and the spot spacing is two-thirds of the full-width-at-
half-maximum for the beam in air at isocenter. The
number of monitor units (MU) to deliver for each spot
was then determined using the simultaneous spot
optimization algorithm [11]. The raw spot weights were
then post-processed to adapt to the treatment machine
limitations, especially those relating to the minimum
number of MUs deliverable per spot, and the resolution
of the monitor chambers responsible for measuring the
MU per spot. During post-processing, the cut-and-ap-
pend repainting strategy was utilized utilized whereby
the dose per painting per energy layer was limited to
0.1 Gy. Repainting is recommended for scanned pencil
beam delivery to mitigate any interplay effects between
the motion of the beam and the motion of the target
[12]. The final dose distribution and DVHs were calcu-
lated using the post-processed spot weights.DVH and statistical analysis
DVHs were analyzed for all of the OARs identified
within the radiation fields. PSPT and IMPT plans were
each compared to the IMRT plan and PSPT was com-
pared directly to IMPT. The paired t-test was used for
all statistical comparisons, with p values less than 0.05
considered significant. P values less than 0.001 were
truncated and noted as p < 0.001.IMPT plan robustness
Assessment of the effect of setup errors on one IMPT
plan was performed by recalculating the dose distribu-
tions with simulated ±3 mm shifts in the three orthog-
onal directions for this patient group. The nominal DVH
statistics from the IMPT plan were then compared with
the DVH band resulting from the simulated setup errors.
Results
OAR comparison of PSPT vs IMRT for PORT
Compared with IMRT plans, PSPT plans spared the lung
dose, however with a concomitant increase in the eso-
phageal and heart doses (Table 1). The mean esophageal
dose increased by 4.6% and the volume received by
40 Gy (V40) increased by 7.3% with PSPT versus IMRT.
There was no significance difference in the mean heart
dose however the heart V40 was significantly higher with
PSPT versus IMRT (36%, p = 0.03). Figure 1 shows the
average DVHs for all 10 patients for each organ at risk.
There was no significant difference between PSPT and
IMRT in the maximum external dose received (p = 0.7).
PSPT produced a 14% reduction in the maximum cord
dose compared with IMRT.
There was an overall reduction in the lung volume
that received low dose, however an increase in the lung
volume received by high dose with PSPT (Table 2).
Figures 2B-D show PSPT (red) yielding a higher volume
irradiated at the high-dose regions compared with IMRT
or IMPT.
OAR comparison of IMPT vs IMRT for PORT
IMPT plans reduced the mean esophageal dose by 3.2%
and there was no significant change in V40. IMPT sig-
nificantly reduced the mean heart dose by 30.7% over
IMRT and there was a trend towards a lower V40 with
IMPT (Table 1).
All lung doses were consistently reduced with IMPT
over IMRT (Table 2).
OAR comparison of IMPT vs PSPT for PORT
IMPT plans reduced the mean esophageal dose by 7.4%
and the V40 by 9% versus PSPT. The mean heart dose
and V40 were significantly reduced by 35.1% (p < 0.001)
and 51.7% (p < 0.001), respectively. There was no sig-
nificant difference between IMPT and PSPT in the ma-
ximum external dose received (p = 0.3). In addition,
IMPT reduced the maximum cord dose by 60% over
PSPT (p < 0.001). There was also a significant reduction
in the dose received by 1% of the spinal cord volume, in-
cluding a 66% reduction with IMPT over PSPT (Table 1).
IMPT yielded large and statistically significant reduc-
tions in all lung doses over PSPT (Table 2). The magni-
tude of benefit of IMPT over PSPT was larger in the
volume receiving higher doses.
Table 1 Dosimetric endpoints for IMRT, PSPT, and IMPT plans including average values, standard deviation, and range
Parameter (%) IMRT PSPT IMPT
Average SD Minimum Maximum Average SD Minimum Maximum Average SD Minimum Maximum
Total lung V5 46.2 6.9 37.4 58.8 35.6 11.5 16.7 57.2 26.9 6.6 17.4 36.6
V10 33.8 7.2 21.2 43.5 30.9 10.2 13.8 49.0 21.2 5.1 12.9 28.9
V20 22.0 5.9 9.1 29.4 22.6 7.6 10.1 36.2 14.4 3.7 7.5 19.8
V30 12.3 3.9 3.9 16.1 15.0 4.4 6.7 21.4 9.1 2.3 3.9 12.3
Mean (cGy) 1083.0 212.8 686.0 1370.5 1003.6 306.8 475.1 1484.1 667.5 160.5 372.2 907.6
Contralateral lung V5 36.7 11.8 24.8 65.8 25.9 14.0 7.3 52.6 17.3 11.1 4.0 42.5
V10 24.2 13.3 9.7 56.9 21.7 13.0 5.0 47.4 13.0 9.6 2.5 36.2
V20 14.8 10.8 1.6 41.1 14.6 10.9 2.4 37.0 8.5 7.9 1.1 28.6
V30 7.6 8.5 0.3 30.4 8.8 7.7 1.0 28.0 5.5 6.1 0.3 21.7
Mean (cGy) 813.1 434.1 404.8 1935.7 673.8 459.3 140.5 1707.0 428.2 351.8 72.7 1313.0
Ipsilateral lung V5 67.0 13.5 45.0 89.1 57.9 19.3 18.1 84.9 49.5 15.1 11.6 64.5
V10 55.9 13.0 33.0 76.4 52.7 17.9 15.5 76.2 41.6 13.6 8.7 55.3
V20 40.5 13.9 14.5 58.5 42.5 14.7 10.4 56.6 30.8 11.2 5.2 41.5
V30 26.8 11.8 3.7 44.5 31.8 11.6 6.7 43.6 21.6 8.8 3.2 32.9
Mean (cGy) 1827.5 481.3 902.1 2482.6 1869.9 631.4 485.8 2504.0 1390.3 471.6 270.0 1869.9
Spinal cord Dmax (cGy) 4018.9 482.5 2777.0 4480.5 3435.9 1096.5 1057.6 4699.6 1354.9 721.9 374.6 2530.6
D1 (cGy) 3281.8 1348.7 80.1 4155.0 2413.4 1182.0 257.0 4364.0 817.6 163.0 515.4 1686.0
Heart V40 7.9 7.0 0.1 23.4 10.8 6.0 1.2 19.0 5.2 4.6 0.2 14.5
Mean (cGy) 1019.8 477.4 264.7 1954.0 1063.0 399.2 368.1 1462.0 688.9 316.7 76.3 1101.5
Esophagus V40 51.5 11.6 30.0 73.7 55.3 10.4 38.6 74.5 50.3 12.4 32.0 74.4
Mean (cGy) 2854.3 616.6 1878.2 4184.2 2985.8 575.9 2074.7 4056.0 2764.3 598.6 1888.3 3997.0
Body Dmax (cGy) 5662.3 82.0 5495.7 5753.2 5688.2 171.7 5237.3 5878.6 5635.2 139.1 5410.9 5805.7

















Figure 1 Average DVHs of 10 patients comparing IMRT (blue), PSPT (red), and IMPT(green), (A) heart, (B) ipsilateral lung, (C)
contralateral lung, (D) total lung-PTV, (E) esophagus.
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All plans maintained adequate coverage of the PTV with
V95 at least 95%. The average V95 for IMRT, PSPT, and
IMPT were 96.0%, 96.2%, and 98.4%, respectively. CTV
and PTV coverage were similar among all three groups,
as shown in Figure 2.
Figures 3 and 4 show patients with stage IIIA NSCLC
status post right upper lobe lobectomy with positive
lymph nodes in station 7 and status post left lower lobe
lobectomy with positive lymph nodes in stations 5 and
12, respectively. In both cases, the dosimetric benefit of
IMPT can be qualitatively appreciated. It is noted thatthe 4500 cGy isodose line approaches the anterior thor-
acic skin in the PSPT plan but generally spared to lower
doses in the IMRT or IMPT plans.
Uncertainty in IMPT plan delivery
Since the treatment fields were mostly anterior, lateral
setup errors resulted in the largest deviation in dose
to the target from the nominal values. For the illustra-
tive case, PTV V95% decreased from 98.1% to 90.2%
(Figure 5A) while CTV V95% decreased from 97.5% to
94.5% (Figure 5B). For the ipsilateral lung (Figure 5C),
V20 increased from a nominal value of 21.7% to a
Table 2 Comparison of PSPT vs. IMRT, IMPT vs. IMRT, and IMPT vs. IMRT for three lung volumes: total lung
(minus PTV), contralateral lung, and ipsilateral lung
PSPT vs. IMRT IMPT vs. IMRT IMPT vs. PSPT
Δ (%) p value Δ (%) p value Δ (%) p value
Total lung V5 −22.8 0.002 −41.7 <0.001 −24.5 0.001
V10 −8.6 0.2 −37.3 <0.001 −31.4 <0.001
V20 2.9 0.7 −34.5 <0.001 −36.4 <0.001
V30 22.1 0.005 −26.2 0.001 −39.6 <0.001
Mean (cGy) −7.3 0.2 −38.4 <0.001 −33.5 <0.001
Contralateral lung V5 −29.4 <0.001 −52.8 <0.001 −33.1 <0.001
V10 22.1 0.006 −26.2 0.001 −39.6 <0.001
V20 −1.7 0.8 −42.5 <0.001 −41.5 0.002
V30 15.7 0.009 −27.5 0.03 −37.3 <0.001
Mean (cGy) −17.1 0.006 −47.3 <0.001 −36.4 <0.001
Ipsilateral lung V5 −13.5 0.02 −26.1 <0.001 −14.6 0.007
V10 −5.8 0.3 −25.6 <0.001 −21.0 <0.001
V20 5.1 0.4 −23.9 <0.001 −27.6 <0.001
V30 18.8 0.007 −19.4 0.009 −32.1 <0.001
Mean (cGy) 2.3 0.6 −23.9 <0.001 −25.6 <0.001
Delta represents change of first technique listed versus baseline comparison technique (second listed).
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shoot in the lungs due to setup errors. For the heart
(Figure 5D), V40 increased from a nominal value of
5.5% to a maximum of 6.3%.
Discussion
We demonstrated that IMPT decreases the dose to all
OARs versus both IMRT and PSPT. This decrease in
dose to OARs theoretically corresponds to a decrease in
the potentia radiation morbidity. Based on this dosi-
metric study, proton beam therapy has the potential to
provide adjuvant radiotherapy that is both safe and effi-
cacious to patients with CR-NSCLC.Figure 2 Average DVHs of 10 patients comparing IMRT (blue), PSPT (
(B) CTV.It is hypothesized that the lack of survival benefit seen
in some PORT studies is due to the adverse effects of
older radiation techniques. In 1998, the PORT meta-
analysis showed a survival decrement for all patients,
but not for patients with N2 disease [2]. A retrospective
subset analysis of the Adjuvant Navelbine International
Trialist Association (ANITA) randomized study of adju-
vant chemotherapy found that for patients with pN2 dis-
ease, PORT improved median survival in patients who
received chemotherapy (23.8 to 47.4 months) and in
those who did not receive chemotherapy (12.7 to 22.
7 months) [5]. A SEER analysis of PORT found a survival
benefit (hazard ratio of 0.855) for N2 patients on subsetred), and IMPT (green) for the target structures: (A) PTV and
Figure 3 Patient with stage IIIA NSCLC status post right upper lobe lobectomy with positive lymph nodes in station 7. Representative
isodose distributions for (A) IMRT (B) PSPT (C) IMPT plans in the axial view. Key demonstrates corresponding dose to colorwash.
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60 and two-dimensional treatment planning. This type of
radiotherapy led to excess heart and lung dose corre-
sponding to both short- and long-term morbidity and
mortality. However, using modern radiotherapy tech-
niques, the risk of death from intercurrent disease (DID)Figure 4 Patient with stage IIIA NSCLC status post left lower lobe lob
Representative isodose distributions for (A) IMRT (B) PSPT (C) IMPT plans inis not excessively increased, as shown by Machtay et. al.
(13.5% with PORT versus 10%) [13].
PBT has the potential to decrease dose to OARs above
standard modern radiotherapy and, therefore, improve
the therapeutic index [14]. Other groups have shown su-
periority of PSPT over 3D-CRT [15] as well as IMPTectomy with positive lymph nodes in stations 5 and 12.
the axial view. Key demonstrates corresponding dose to colorwash.
Figure 5 DVH bands of the targets (A), (B) and organ at risks (C)-(E). The nominal DVH is shown as the black line while dotted lines are
results from lateral, vertical and longitudinal setup errors of 3mm. The worst case DVH results from lateral setup errors.
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There are two unique aspects of post-operative radio-
therapy that make proton beam therapy a particularlywell-suited treatment. First, unlike in the definitive set-
ting, the target structure is midline and anterior with-
out extension into the lung parenchyma. This is easily
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Alternatively, an incline gantry arrangement may allow
for a non-coplanar beam arrangement which could de-
crease the dose to the heart even further. Second, in de-
finitive treatment, the therapeutic index is inherently
wider since radiotherapy is the only method of local
control whereas, in PORT, surgery is the primary treat-
ment and radiotherapy is given adjuvantly. Therefore,
the risk of adverse effects with PORT must be smaller
than with definitive RT and PBT could help minimize
these risks.
Radiation-induced lung injury (RILI), including pneu-
monitis and pulmonary fibrosis, is the most significant
contributor to the morbidity and mortality of PORT. We
demonstrate IMPT decreases lung doses of up to 41%
versus PSPT and up to 53% versus IMRT. While PSPT
reduced the low-dose lung bath versus IMRT, there was
an increase in the high-dose volume irradiated.
The clinical implications of these findings are that
IMPT may decrease the incidence of RILI. Dose-volume
relationships including the MLD, V5, V15 and V20 have
been correlated with risk of pneumonitis [17-19]. The
development of RILI also depends on field size [3], use
of chemotherapy, baseline pulmonary function, and gen-
etic polymorphisms in the ATM-P53 and base excision
repair (XRCC1,APEX1) pathways [20]. IMPT, shown to
reduce all examined lung parameters, should reduce
RILI; it is unclear if PSPT would also lead to a clinically
significant decreased incidence of RILI.
PORT has been shown to increase heart disease mor-
tality, although not when examining patients treated
with modern radiotherapy techniques [21]. We show a
large reduction in mean heart dose and V40 with IMPT
versus IMRT and PSPT but an increase with PSPT over
IMRT, likely from an improved ability of IMPT to con-
form to a complicated CTV. Given the concern for heart
morbidity, we recommend that caution be taken when
treating the mediastinum with PSPT. Although IMPT
treatment planning shows promising results in terms of
RT-induced cardiac toxicity, motion management and
repainting delivery techniques should be employed in
order to ensure accurate delivery of the treatment plan.
Proton planning has inherent uncertainties, including
inhomogeneity. In PSPT, as the beam passes through a
low density structure (e.g. lung), its distal edge is de-
graded. With IMPT, this degradation is limited and the
distal margin can be truncated accordingly as the distal
target pencil beam energies and intensities are optimized
to cover the distal target without degradation. In PSPT,
the compensator is smeared to account for setup uncer-
tainties and motion to ensure target coverage. This can
have dramatic effect in the distal dose distribution for
lung treatment due to the presence of lung tissue in the
beam path. In IMPT, setup uncertainties and motion canalso have a dramatic effect on dose homogeneity. The
magnitude of these errors depends on the internal dose
gradients as well as the pencil beam widths [22]. Active
motion management, with 4D CT implemented as either
prospective gated imaging or retrospective correlative
imaging may be a way to reduce some of these uncer-
tainties and further clinical investigations are necessary
to confirm this.
Robustness of IMPT plans against setup and range un-
certainties is a topic of active research [23]. In particular,
setup errors lateral to the beam direction may result in
large overshoot into the surrounding lung tissue, negat-
ing any potential lung benefit that IMPT may offer over
other modalities. In PSPT, this effect is taken into ac-
count in the planning process through compensator
smearing. For IMPT, Pflugfelder [24] and Liu [25] have
proposed incorporating geometrical and range uncer-
tainties within the robust optimization framework by
taking into account the worst case dose distribution in
the objective function, thereby ensuring that the target
dose is more homogeneous and OAR doses are less sen-
sitive to these uncertainties. In this work, we presented
one illustrative case of the uncertainties in the IMPT
dose distribution arising from setup errors. The results
indicated that PTV coverage may drop by 8% and the
CTV coverage by 3%. OAR doses are also sensitive to
setup uncertainties but the nominal DVHs tends to lie
in the middle of the DVH bands.
Another uncertainty with PBT is inter- and intra-
fraction organ and target motion. While motion of the
mediastinum is less than a distal lung tumor, it is none-
theless present. At our institution, we account for this
with 4D simulation for all patients who undergo thoracic
radiotherapy (PSPT), as studies have shown that by ac-
counting for motion at the time of simulation, CTV
coverage is adequate throughout radiotherapy [26]. Is-
sues of dynamic delivery and tumor motion are more
significant with IMPT than PSPT; dose repainting with
fractionated IMPT and active motion management even
for small amplitude motion may be necessary. Further
studies need to be performed to examine this interplay
effect which has been shown to cause a possible differ-
ence in dose of up to 10% [27] but can be mitigated by
beam rescanning.Patients have been treated at our insti-
tution with PSPT to the mediastinum, and we have
found the same dosimetric benefit as is demonstrated in
this study when motion was taken into consideration. As
technology with IMPT further advances, we anticipate a
similar dosimetric benefit with motion consideration as
seen in this study.
Other notable findings include a decrease in esopha-
geal and cord doses by IMPT over PSPT. The changes
in magnitude are smaller than seen in the heart and lung
doses, largely due to the esophagus abutting or even
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dose may correspond to a decrease in treatment-related
esophagitis, a dose-limiting acute toxicity. There were
significant reductions in the cord dose. Although cli-
nically-significant cord toxicity is rare in NSCLC, this
large reduction could permit dose-escalation in cases of
positive margins and gross residual disease. It is notable
that the skin dose is higher with proton therapy than
IMRT, which could result in greater acute skin toxicity
and erythema. Overall, the long-term potential bene-
fits of IMPT on the lung and heart outweigh its pos-
sible increased skin toxicity which resolves shortly after
radiotherapy.
We utilized DVH constraints identical to those used at
our institution for proton and IMRT plans. All contou-
ring was performed by a single physician (ABM) and a
single physicist (KT) performed all ten treatment plans
to minimize designer bias.
Secondary particles including neutrons may theoretic-
ally deliver dose outside of the target volume (in PSPT,
from the treatment nozzle; in IMPT, from interactions
with nuclei of tissue). There is no published evidence
of an increase in secondary malignancies from neu-
tron dose from PBT; however, this remains an area of
uncertainty in our calculations and long-term effects.
In summary, compared with IMRT and PSPT, IMPT
had a statistically significant and large decrease in dose
to all OARs, most notably the lung and heart, all while
maintaining excellent target coverage. PSPT, while re-
ducing the volume of lung receiving a higher dose, in-
creases the low-dose bath and increases certain heart
dosimetric parameters. The clinical implications are that
IMPT will hopefully reduce the adverse effects of PORT
and improve the therapeutic index when employed in
conjunction with active motion management and repain-
ting techniques.
At the University of Pennsylvania, there are ongoing
phase II trials utilizing proton beam therapy in the de-
finitive setting for NSCLC. At MD Anderson Cancer
Center and Massachusetts General Hospital, there is a
randomized trial of proton versus photon therapy for lo-
cally advanced lung cancer. In the post-operative setting,
phase I/II trials are necessary to correlate the clinical
significance of the finding of this study and clarify the
role of IMPT in the post-operative treatment of NSCLC.
Subsequently, a randomized phase III trial could be de-
signed comparing proton and photon therapy for PORT
of resected NSCLC with a primary endpoint of reducing
cardiopulmonary toxicity.
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